Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and Switzerland

Clinical Outcomes ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Treatment Patterns ◽

Routine Clinical Practice ◽

Minimal Residual ◽

Disease Testing

PCN39 TREATMENT PATTERNS, MINIMAL RESIDUAL DISEASE (MRD) TESTING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PATIENT CHART REVIEW IN BELGIUM, GREECE AND SWITZERLAND

Value in Health ◽

10.1016/j.jval.2019.09.236 ◽

2019 ◽

Vol 22 ◽

pp. S442-S443

Author(s):

A. Spyridonidis ◽

D. Deeren ◽

W. Bouwmeester ◽

C. Giannopoulou ◽

K. Nickel ◽

...

Keyword(s):

Clinical Outcomes ◽

Chart Review ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Treatment Patterns ◽

Patient Chart ◽

Testing Patterns ◽

Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma

Minimal Residual Disease Testing ◽

10.1007/978-3-319-94827-0_2 ◽

2018 ◽

pp. 23-68

Author(s):

Laura Wake ◽

Xueyan Chen ◽

Michael J. Borowitz

Keyword(s):

Residual Disease ◽

Lymphoblastic Leukemia ◽

Minimal Residual ◽

Disease Testing

Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.7013 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 7013-7013 ◽

Cited By ~ 5

Author(s):

Elias Jabbour ◽

Nicola Gökbuget ◽

Anjali S. Advani ◽

Matthias Stelljes ◽

Wendy Stock ◽

...

Keyword(s):

Clinical Outcomes ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Inotuzumab Ozogamicin ◽

Phase 3 ◽

Minimal Residual Disease Detection in Adults with Acute Lymphoblastic Leukemia By Next Generation Sequencing: Impact on Clinical Outcomes

Transplantation and Cellular Therapy ◽

10.1016/s2666-6367(21)00160-3 ◽

2021 ◽

Vol 27 (3) ◽

pp. S125

Author(s):

Lissette Cervantes ◽

Lan Y Wang ◽

George Yaghmour ◽

Andrei Varnavski ◽

Imran Siddiqi

Keyword(s):

Next Generation Sequencing ◽

Clinical Outcomes ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Disease Detection ◽

Next Generation ◽

Generation Sequencing ◽

Cross-sectional physician survey on the use of minimal residual disease testing in the management of pediatric and adult patients with acute lymphoblastic leukemia

Hematology ◽

10.1080/10245332.2018.1510068 ◽

2018 ◽

Vol 24 (1) ◽

pp. 70-78 ◽

Cited By ~ 1

Author(s):

Christopher Kim ◽

Kara Delaney ◽

Michelle McNamara ◽

Victoria Chia ◽

Vadim Romanov

Keyword(s):

Residual Disease ◽

Lymphoblastic Leukemia ◽

Adult Patients ◽

Physician Survey ◽

Cross Sectional ◽

Minimal Residual ◽

Disease Testing

Improving Diagnostic Methods for Minimal Residual Disease Detection (MRD) in Childhood Acute Lymphoblastic Leukemia (ALL)

Klinische Pädiatrie ◽

10.1055/s-0034-1374837 ◽

2014 ◽

Vol 226 (03) ◽

Author(s):

A Szymansky ◽

S Groeneveld-Krentz ◽

J Hof ◽

R Kirschner-Schwabe ◽

C Eckert

Keyword(s):

Residual Disease ◽

Lymphoblastic Leukemia ◽

Diagnostic Methods ◽

Childhood Acute Lymphoblastic Leukemia ◽

Disease Detection ◽

Minimal Residual Disease Detection ◽

Faculty Opinions recommendation of Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14267017.15779136 ◽

2012 ◽

Author(s):

Jan Starý ◽

Jana Volejnikova

Keyword(s):

Treatment Outcome ◽

Induction Therapy ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Early Response ◽

Childhood Acute Lymphoblastic Leukemia ◽

Response To Treatment ◽

Faculty Opinions recommendation of Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3974956.3733054 ◽

2010 ◽

Author(s):

Sheila Weitzman ◽

Sumit Gupta

Keyword(s):

Clinical Significance ◽

Induction Therapy ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Childhood Acute Lymphoblastic Leukemia ◽

Remission Induction ◽

Low Levels ◽

Faculty Opinions recommendation of Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718266974.793496733 ◽

2014 ◽

Author(s):

Jan Starý ◽

Michaela Kotrová

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Minimal Residual ◽

Philadelphia Chromosome Positive

Faculty Opinions recommendation of Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725382591.793524768 ◽

2016 ◽

Author(s):

Jan Starý

Keyword(s):

High Risk ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Prognostic Relevance ◽